CTOs on the Move

CytoDyn

www.cytodyn.com

 
CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection. We have one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which prevents viral entry into healthy T-cells by blocking the HIV co-receptor CCR5. The drug candidate is also being tested for other immunological conditions, and has been granted FDA orphan drug status for the treatment of Graft versus Host Disease (GvHD) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are undergoing bone marrow ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cytodyn.com
  • 1111 Main Street Suite 660
    Vancouver, WA USA 98660
  • Phone: 360.980.8524

Executives

Name Title Contact Details
Nitya Ray
 Chief Technology Officer Profile

Funding

CytoDyn raised $15M on 03/31/2020

Similar Companies

QED Therapeutics

QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders.

Santarus, Inc.

Santarus, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Teva parenteral Medicines

Teva parenteral Medicines is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ambys

Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies for people with advanced liver disease. Founded by world-renowned experts in liver disease and regenerative medicine, Ambys is pioneering the application of novel modalities including cell and gene therapy, and gain-of-function drug therapy, to meet the urgent need for treatments that have the potential to restore liver function and prevent the progression to liver failure across multiple liver diseases that are untreatable or poorly treated today. Ambys was launched in 2018 by Third Rock Ventures and Takeda Pharmaceuticals with $140M in starting capital and is headquartered in South San Francisco, Calif.

Arisaph Pharmaceuticals

Arisaph Pharmaceuticals is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.